SHANGHAI SHENQI PHARMACEUTICAL INVESTMENT MANAGEMENT CO., LTD. Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Stock
Equities
600613
CNE000000453
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.03 CNY | +0.50% |
|
-0.50% | -20.76% |
| Sales 2021 | 2.3B 318M | Sales 2022 | 2.39B 330M | Capitalization | 4.22B 583M |
|---|---|---|---|---|---|
| Net income 2021 | 69M 9.52M | Net income 2022 | 48M 6.63M | EV / Sales 2021 | 1.35 x |
| Net cash position 2021 | 182M 25.06M | Net cash position 2022 | 371M 51.2M | EV / Sales 2022 | 1.61 x |
| P/E ratio 2021 |
49.4
x | P/E ratio 2022 |
91.4
x | Employees | 1,570 |
| Yield 2021 |
1.56% | Yield 2022 |
1.22% | Free-Float | 49.01% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.50% | ||
| 1 week | -0.50% | ||
| Current month | -6.80% | ||
| 1 month | -9.46% | ||
| 3 months | -6.80% | ||
| 6 months | -21.89% | ||
| Current year | -20.76% |
1 week
5.68
6.12
1 month
5.616.82
Current year
4.657.79
1 year
4.659.31
3 years
4.4514.20
5 years
3.7414.20
10 years
3.7428.57
| Managers | Title | Age | Since |
|---|---|---|---|
Bin Feng
CEO | Chief Executive Officer | 52 | 05-06-30 |
Ke Jing Wu
SEC | Corporate Secretary | 47 | 17-04-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shi Gui Chen
BRD | Director/Board Member | 61 | 20-06-28 |
Bin Feng
CEO | Chief Executive Officer | 52 | 05-06-30 |
Zhi Ting Zhang
BRD | Director/Board Member | 80 | 20-06-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 6.03 | +0.50% | 4,753,000 |
| 24-04-22 | 6 | +0.84% | 4,476,394 |
| 24-04-19 | 5.95 | +0.51% | 4,383,605 |
| 24-04-18 | 5.92 | -2.79% | 6,576,300 |
| 24-04-17 | 6.09 | +8.17% | 7,895,100 |
End-of-day quote Shanghai S.E., April 22, 2024
More quotes
Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. is a China-based company principally engaged in research and development, manufacture and sale of pharmaceuticals. The Companyâs products are targeted for the treatment of influenza, cardio cerebrovascular diseases, rheumatoid bone diseases and in the areas of oncology, antifungal, antipyretic and gynaecology. The Company's main products include cantharidin sodium vitamin B6 injection, cantharidin sodium injection and other Chinese patent drug products. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -20.76% | 430M | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
- Stock Market
- Equities
- 600613 Stock
